Efficacy of tocilizumab for interstitial lung disease in an undifferentiated autoinflammatory disorder partially responsive to anakinra

Rheumatology (United Kingdom)

Volumn 53, Issue 3, 2014, Pages 573-574

  Keidel, Sarah M ^a   Hoyles, Rachel K ^b   Wilkinson, Nick M R ^a  

^a NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; COMORBIDITY; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; LUNG DISEASES, INTERSTITIAL; TREATMENT OUTCOME; URTICARIA; VASCULITIS;

EID: 84894358473     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket211     Document Type: Letter

References (6)

1. Erkan F, Gul A, Tasali E. Pulmonary manifestations of Behcet's disease. Thorax 2001;56:572-8.
2. Davatchi F, Shahram F, Chams-Davatchi C et al. Behcet's disease in Iran: analysis of 6500 cases. Int J Rheum Dis 2010;13:367-73.
3. Yokota S, Imagawa T, Mori M et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled, withdrawal phase III trial. Lancet 2008;371:998-1006.
4. Krause K, Feist E, Fiene M et al. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol 2012;129:848-50.
5. Hirano T, Ohguro N, Hohki S et al. A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 2012;22:298-302.
6. Shapiro L, Farrell J, Haghighi AB. Tocilizumab treatment for neuro-Behcet's disease, the first report. Clin Neurol Neurosurg 2012;114:297-8.